・Novo Nordisk’s U.S.-listed shares closed 8.8 per cent lower after ziltivekimab failed a pivotal cardiovascular trial. ・The drug produced the expected biological response but did not reduce ...

Add Yahoo as a preferred source to see more of our stories on Google. For years, heart doctors believed they might finally have a new way to prevent heart attacks and strokes in millions of people.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cardiovascular disease remains the world's leading cause of death, making treatments for heart disease among the pharmaceutical industry's most valuable assets. Analysts expect the global ...

By Ellyn Vohnoutka HealthDay ReporterWEDNESDAY, Sept. 9, 2026 (HealthDay News) — A drug that heart doctors widely expected to become the next major weapon against heart attacks has failed in a large ...

Amarin (AMRN) on Friday said a new analysis of its REDUCE-IT trial found that patients who remained on icosapent ethyl for at least 18 months experienced about a 30% reduction in the relative risk of ...

A centuries-old heart drug costing less than ten cents a day could help keep heart-failure patients out of the hospital. New research suggests low-dose digoxin can reduce heart-failure ...